Advanced haemodynamic monitoring remains a cornerstone in the management of the critically ill. While rates of pulmonary artery catheter use have been declining, there has been an increase in the number of alternatives for monitoring cardiac output as well as greater understanding of the methods and criteria with which to compare devices. The PiCCO (Pulse index Continuous Cardiac Output) device is one such alternative, integrating a wide array of both static and dynamic haemodynamic data through a combination of trans-cardiopulmonary thermodilution and pulse contour analysis. The requirement for intra-arterial and central venous catheterisation limits the use of PiCCO to those with evolving critical illness or at high risk of complex and severe haemodynamic derangement. While the accuracy of trans-cardiopulmonary thermodilution as a measure of cardiac output is well established, several other PiCCO measurements require further validation within the context of their intended clinical use. As with all advanced haemodynamic monitoring systems, efficacy in improving patient-centred outcomes has yet to be conclusively demonstrated. The challenge with PiCCO is in improving the understanding of the many variables that can be measured and integrating those that are clinically relevant and adequately validated with appropriate therapeutic interventions.
Advanced
haemodynamic monitoring has remained a cornerstone in the management of the critically ill since the introduction of the pulmonary artery catheter into clinical practice in the 1970s 1 . The pulmonary artery catheter is still to a large extent the clinical reference standard for cardiac output measurement, but its utility is increasingly questioned and use appears to be declining 2, 3 . Technological advances coupled with both the recognition of costs 4 , complications 5 and a failure to demonstrate mortality benefit 6, 7 with the pulmonary artery catheter has driven the demand for less invasive alternatives.
Despite a substantial increase in the number of publications comparing haemodynamic monitoring devices 8 , there are several reasons why their appropriate role in clinical practice remains uncertain. First, cardiac output and other advanced haemodynamic measurements can be derived through a variety of unrelated methods, each with important benefits and limitations requiring consideration. Second, the aortic flow probe as the accepted gold standard for cardiac output measurement is impractical and highly invasive and in the clinical setting is substituted for a reference device with known but imperfect characteristics 9 . Third, valid statistical methods with which to compare devices and the relationship between statistical significance and thresholds for clinical decision-making remain the subject of debate, although there appears to be agreement that the majority of comparative studies to date are suboptimal [8] [9] [10] [11] . Fourth, the ultimate aim of monitoring a specific parameter is the belief that responding to the measurements will lead to an improvement in patient survival or function. However, evaluating the effectiveness of a monitoring device is complex, requiring a valid measurement to be coupled with accurate clinical interpretation and initiation of a beneficial therapeutic intervention in an appropriate patient population. Finally, no single device currently fulfils all the criteria to be considered an ideal advanced haemodynamic monitor as summarised in Table 1 and by others elsewhere 12 . The choice of most appropriate monitor may vary, requiring consideration of its unique characteristics and the circumstances in which it will be used.
The PiCCO (Pulse index Continuous Cardiac Output) monitor measures and integrates a wide array of haemodynamic variables through intraarterial and central venous catheterisation alone. As such it is considered a less invasive monitor of cardiac output than the pulmonary artery catheter, although the need for arterial and venous catheterisation renders it more so than so-called minimally or non-invasive devices (see Table 2 for a comparison of advanced haemodynamic monitoring devices).
Having been in use for over 10 years, a substantial number of studies of PiCCO exist, including comparisons to a range of monitoring alternatives. The aim of this review therefore was to provide a summary of the current role of PiCCO in the clinical context by describing its practical use, the underlying physiological basis for the parameters measured, and their validity and clinical utility. A glossary of terms is provided in the Appendix.
PRACTICAL USAgE
The most established commercially available complete PiCCO set is produced by Pulsion Medical Systems, germany. It consists of three main components, an arterial catheter with a solid-state thermistor 5 mm from its tip, an injection device that connects to the distal lumen of a standard central venous catheter and the user-interface monitor 24 . The latest model is the PiCCO 2 which includes a 13 inch colour liquid crystal display touchscreen that can display all standard clinical parameters. Alternatively, both Philips (PiCCO-Technology Module, Andover, MA, USA) and Dräger (Infinity ® PiCCO SmartPod ® , Lübeck, germany) have modular attachments for their monitor range to allow use of a Pulsion PiCCO arterial catheter and central venous catheter injectate device with these monitors. More recently, an alternative to the Pulsion system has been developed by Edwards Lifescience (Irvine, CA, USA, EV1000 clinical platform and VolumeView sensor) although comparative data are currently lacking 25 .
Patient selection
none of the large (and increasing) number of devices currently available for measuring cardiac output can be considered universally ideal (Table 1) . given the lack of comprehensive criteria to determine when invasive haemodynamic monitoring should be initiated, PiCCO may be considered in all patients in whom central venous and intraarterial cannulation is deemed necessary. Risks associated with insertion of the PiCCO arterial catheter appear to be low 26 , and although difficult to quantify, a greater risk is likely to result from therapy initiated on the basis of inaccurate data measurement or its inappropriate interpretation or contextualisation. While the benefit of PiCCO is most likely to be apparent in those with evolving critical illness or at high-risk of severe haemodynamic derangement, in practice PiCCO is generally employed in patients in one of three main categories:
1. Intraoperative and early postoperative management of patients in whom complex comorbidities are present or particular fluid management strategies are considered to be beneficial. For example, restricted fluid use 29 . Contraindications to use fall into two categories. First, contraindications to vascular device insertion including severe peripheral vascular disease, arterial grafting, overlying infection and coagulopathy. Second, anatomical or physiological derangements likely to render PiCCO-derived measurements grossly inaccurate. These are further described in the section on PiCCO parameters.
Site selection and catheter insertion
Clinically important differences may exist in both the absolute values of arterial pressure measured at more peripheral compared with more central sites 30 as well as the shape of the arterial pressure wave-form. The femoral artery is the most common site of cannulation, however radial, brachial and axillary sites are potential alternatives. Removal of the arterial catheter is recommended within 10 days of insertion and replacement of the arterial line transduction kit and inline injectate sensor housing is required every three to five days 24 .
The venous injectate port should be placed in the central cardiopulmonary circulation, within or directly proximal to the right atrium. Placement in the femoral vein will result in significant overestimation of intrathoracic volumetric measurements although trans-cardiopulmonary thermodilution cardiac output measurement may still be reliable 31 . In addition, cannulation of the ipsilateral femoral artery should be avoided to reduce temperature artefact from injection close to the thermistor in the nearby artery 32 .
Performing a calibration
Following catheter insertion and monitor setup with a mandatory data set, calibration is required before data acquisition. The injectate solution should ideally be 0.9% saline as both lipid and dextrose compounds can damage the sensor's housing 24 . The recommended volume for injection is directly proportional to the patient's extravascular thermal volume and therefore depends on both patient's weight and the amount of extravascular lung water (EVLW). In practice between 15 and 30 ml per injection is normally used. The optimal fluid temperature is below 8°C although room temperature solutions are acceptable 33 . Three separate injections within a five-minute period performed by the same person at the same speed and pressure should yield results with <20% variation. Calibration should be repeated every eight hours or following a major change in the patient's clinical condition 34 .
Goal-directed use
In an attempt to provide an appropriate response to the values displayed, a decision tree model has been proposed by the manufacturers of PiCCO 24 . The clinical response to the data provided can be divided into expectant, volume loading, volume reduction and use of vasoactive medication. This structured approach couples standardised interventions to specific data patterns but must only be considered in the context of a global clinical assessment and suffers from several shortcomings. First, the presence of serious reversible pathology should also be explored and corrected as a cause of haemodynamic derangement. For example, the decision tree does not direct a clinician to decompress a pneumothorax or provide source control in the event of sepsis. Second, it does not encompass consideration of mechanical support devices such as intra-aortic balloon counter-pulsation or venoarterial extracorporeal membrane oxygenation.
Whereas the vast majority of the literature comparing cardiac output monitoring devices provides a comparison between specific isolated variables, clinical practice demands that all available information be assimilated to guide decisionmaking 35 . The particular attraction of goal-directed use of PiCCO therefore, is in its capacity to integrate a large number of haemodynamic parameters. In this regard, few pragmatic studies of the efficacy of PiCCO monitoring in representative perioperative and intensive care settings exist. Results in selected patient groups such as postoperative cardiac surgery are preliminary but encouraging 36 , and reflect similar benefit seen in surrogate outcomes such as hospital length of stay from perioperative studies of goal-directed therapy using minimally invasive monitors 37 .
Estimates of the true accuracy and precision of PiCCO compared with other cardiac output devices are variable and currently unreliable. Issues include differences in the patient groups studied, comparative statistics, study methodology, timing of assessments and imprecision of the pulmonary artery catheter itself as the most common clinical reference. A broad overview is provided in Table 2 with comparative data where available.
PICCO PARAMETERS
The PiCCO device measures and displays a wide array of haemodynamic data (see Table 3 for a summary of the parameters and quantification of their potential utility). These can be divided into intermittent measurements based on transcardiopulmonary thermodilution and continuous measurements based on pulse contour analysis of the arterial pressure waveform. A further important distinction must be made between directly measured values and those that have been derived and susceptible to compounding of errors ( Table 3) .
Interpretation of the trans-cardiopulmonary thermodilution indicator-time curve allows estimation of cardiac output, EVLW, global enddiastolic volume (gEDV), intrathoracic blood volume (ITBV), cardiac function index and global ejection fraction. Pulse contour analysis provides continuous estimation of stroke volume, cardiac output, pulse pressure variation, stroke volume variation and an index of left ventricular contractility. PiCCO 2 also allows continuous monitoring of central venous oxygen saturation (S cv O 2 ) with the addition of a CeVOX fibreoptic probe inserted through the distal lumen of the central venous catheter.
Evaluation of the validity of these measures can be approached using the framework proposed in Table 4 . Equally important is an understanding of the underlying physiological principles from which they are derived, for which much of the pioneering work was undertaken as far back as the late 19th century 38, 39 . The measurement of cardiac output by thermodilution is based on the Stewart-Hamilton equation 40 , in which cardiac output is inversely related to the concentration and total passage time of an indicator solution measured after its transit through the heart. Adaptation of the original equation for a thermal indicator requires the addition of a constant (K) to correct for the specific thermal mass of the injectate and blood a. The accuracy* of the reference method is known and is clinically acceptable b. The precision † of the reference method is reported for the study population The pulmonary artery catheter is based on indicator transit through only the right side of the heart with a sensor placed in the pulmonary artery. In contrast, in trans-cardiopulmonary thermodilution a known quantity of cold injectate is delivered via a central venous catheter and mixing of the thermal indicator occurs as it passes through the right atrium and ventricle, pulmonary circulation, left atrium, ventricle and aorta. A thermistor-tipped arterial line quantifies the change in temperature over time in a large proximal artery, most commonly the femoral artery. A mono-exponential transformation of the curve with extrapolation of a truncated descending limb back to baseline allows calculation of area under the curve for cardiac output measurement. A comparison of trans-cardiopulmonary thermodilution with pulmonary artery thermodilution and the qualitatively similar resultant curves is shown in Figure 1 .
Compared with the measurement of cardiac output by pulmonary artery thermodilution, transcardiopulmonary thermodilution has been shown to demonstrate a level of accuracy that is within a clinically acceptable range in a number of different patient populations and a recent summary of the comparative studies is provided by Reuter et al 41 . Potential sources of error common to both include loss of injectate prior to delivery, regurgitant valve lesions 42 , intra-cardiac shunts, extracorporeal circulations, rapid changes in body temperature 43 , conductive rewarming of the injectate during transit and the cyclical change in cardiac output that occurs with respiration 44 . Compared with pulmonary artery thermodilution, the greater transit time and distance between injectate delivery and measurement with trans-cardiopulmonary thermodilution will tend to increase the error associated with conductive loss and recirculation while reducing the potential for the measured cardiac output to be unrepresentative of its true value over the entire respiratory cycle 44, 45 . Specific to PiCCO, a large aortic aneurysm will result in overestimation of ITBV and gEDV if femoral artery cannulation is used, while intra-aortic balloon pumps reduces the accuracy of pulse contour analysis measurement of cardiac output but not when derived from transcardiopulmonary thermodilution 46 .
Despite the limitations of thermodilution as a measurement technique and a failure of large randomised trials of pulmonary artery catheter use to demonstrate mortality benefit, enthusiasm for cardiac output monitoring appears undiminished. Although one advantage of PiCCO over pulmonary artery catheter is in dispensing with the need for right heart catheterisation, significant adverse events directly attributable to pulmonary artery catheter insertion are low 6, 47 . The greater potential for PiCCO to demonstrate benefit where the pulmonary artery catheter failed is in the integration of reliable cardiac output measurement with other potentially useful haemodynamic parameters. Demonstration of efficacy will require a greater understanding of the relationship between haemodynamic measurements and patient outcome, allowing monitoring results to be coupled with beneficial therapeutic interventions.
Derivation of additional measures by trans-cardiopulmonary thermodilution
Further analysis of the slope and duration of the thermal indicator dilution curve after passage through both sides of the heart and pulmonary circulation enables estimation of additional haemodynamic parameters including measures of intrathoracic volumes and cardiac function (Figures 1 and 2) . The extrapolated and logtransformed slope of the indicator timeconcentration curve as it returns to baseline is represented by the exponential decay time. Assuming a model of the circulation in which the indicator solution has undergone mixing in a series of chambers, the exponential decay time is proportional to the volume of distribution of the largest chamber, represented by the pulmonary circulation in the case of trans-cardiopulmonary thermodilution. The mean transit time of the indicator solution is the time taken for half the indicator to pass the arterial detection point and is proportional to the total intrathoracic volume of distribution 48 . These measurements are used to calculate EVLW and gEDV which like cardiac output may be indexed to body surface area (Figure 2 ). Derived measurements indexed to body surface area may be misleading in the morbidly obese if calculations are based on actual weight 49 . In the latest PiCCO system however, indexed measurements are derived from ideal weight estimated from measured height, adding a different potential source of error. Additionally, there are a considerable number of paediatric studies evaluating PiCCO use [50] [51] [52] . The accuracy of trans-cardiopulmonary thermodilution as a method of estimating cardiac output appears similar to that of the adult population although conclusive safety data is lacking and the validity of some of the additional trans-cardiopulmonary thermodilution-derived parameters, such as EVLW, are uncertain 53 .
Anaesthesia and Intensive Care, Vol. 40, No. 3, May 2012 Extravascular lung water EVLW is the water content outside of the pulmonary vasculature including the pulmonary interstitium plus any alveolar fluid. The normal range is 3 to 7 ml/kg 54 . Imaging modalities such as computer tomography, magnetic resonance imaging and positron emission tomography have all been used to quantify EVLW however gravimetry is considered to be the gold standard 55, 56 .
The calculation of EVLW by trans-cardiopulmonary thermodilution was initially based on a double indicator method whereby the volume of distribution of an indicator contained within the ITBV (e.g. an inert chemical such as indocyanine green) was subtracted from the volume of distribution of an indicator such as cold water distributing to the total intrathoracic thermal volume. The difference between the intrathoracic thermal volume and the ITBV is equal to the EVLW. Double-indicator trans-cardiopulmonary thermodilution is able to detect changes in EVLW of 20% or more with good correlation to gravimetry 57 .
An eloquent sequence of calculations allows the use of thermal injectate as a single indicator to estimate EVLW with reasonably good correlation to both the double indicator technique (Figure 2) 58 and the gold standard gravimetry technique, albeit with a slight bias of overestimation due to thermal redistribution in extra-pulmonary tissue 59 . Calculation of the ITBV is based on the extrapolation of gEDV and assumes a linear relationship between the two 58, 60 . For both methods, there is also the assumption that the extravascular water content of the myocardium and non-pulmonary vessels is insignificant in comparison to the total EVLW 48 . Potential sources of error include those common to trans-cardiopulmonary thermodilution calculation of cardiac output. In addition, lung resection, obstruction of major pulmonary vessels and potentially also large increases in positive end-expiratory pressure may lead to unreliable measurement of EVLW 61 .
Trans-cardiopulmonary thermodilution calculation of EVLW has been proposed as a diagnostic tool both to measure sub-clinical pulmonary oedema not apparent on clinical examination or plain radiography and to differentiate hydrostatic and inflammatory aetiologies of pulmonary oedema on the basis of the pulmonary vascular permeability index, the ratio of EVLW to PBV 62, 63 . Several small studies demonstrate the ability of transcardiopulmonary thermodilution to measure different changes in fluid compartment distribution in inflammatory and non-inflammatory conditions; further work is required in order to ascertain whether this will translate into clinically meaningful results 63 .
As well as its diagnostic utility, EVLW measurement may have utility both prognostically in predicting survival in those admitted to ICU 64 , and therapeutically by providing a measurement against which to titrate fluid balance. There is increasing evidence of the association between fluid balance and outcomes in critical illness 65, 66 and preliminary studies suggest EVLW measurement may have a role in the management of volume status in a variety of patient groups including lung transplantation 67 , acute lung injury 68 and coronary artery bypass grafting 69 . Whether titration of volume status to EVLW measurements will lead to generalised improvements in patient outcomes remains to be determined.
Global end-diastolic volume and intrathoracic blood volume
Accurate determination of intravascular volume status is important as inappropriate fluid administration is associated with an increased risk of adverse outcomes in critical illness 66, 70 . Central venous pressure, a widely used endpoint for volume resuscitation in the critically ill 71 , and other pressure-based surrogate measures of preload including pulmonary artery occlusion pressure are dependent on several factors other than mean circulatory filling pressure 72, 73 and their utility in predicting volume responsiveness is questionable [74] [75] [76] . Compared with pressure-based measures, gEDV and ITBV or their indexed equivalents gEDVI and ITBVI are volumetric measures of preload derived from features of the trans-cardiopulmonary thermodilution curve using the PiCCO device ( Figure 2 ). gEDV is a measure of the total volume in all four chambers of the heart at end-diastole, whereas ITBV also includes the volume in the pulmonary circulation. Although their reference ranges are different and their relationship under varying haemodynamic conditions may not be linear, from the point of view of clinical interpretation they have equivalent utility. ITBV is simply extrapolated from gEDV when derived by PiCCO using a single thermal indicator 58 .
One-off baseline measures of preload, whether pressure-or volume-based appear equally poor in predicting volume responsiveness 77, 78 . The relationship between stroke volume and change in preload measurement in response to fluid bolus appears stronger for volumetric measures than central venous pressure or pulmonary artery occlusion pressure but still with only moderate correlation 60, 79 . Furthermore, few studies evaluate whether the information from invasive monitoring provides additional benefit over clinical judgement and most involving trans-cardiopulmonary thermodilution are also limited by the potential for mathematical coupling between calculation of cardiac output and volumetric indices 80 .
Compared with both static pressure-and volumebased measures of preload, dynamic measures such as stroke volume variation, pulse pressure variation and systolic pressure variation, have greater accuracy in predicting volume status in mechanically ventilated patients and are described in the section below 81 .
Cardiac function index and global ejection fraction
The PiCCO device calculates two specific measures of cardiac performance based on the trans-cardiopulmonary thermodilution curve. Cardiac function index (the ratio of cardiac output to gEDV) and global ejection fraction (the ratio of stroke volume to gEDV multiplied by a factor of 4) are simply derived as ratios of cardiac output and volumetric measurements. given the known accuracy of trans-cardiopulmonary thermodilution in estimating cardiac output and gEDV it is perhaps unsurprising that cardiac function index and global ejection fraction correlate with cardiac function [82] [83] [84] . In general however, derived indices should be avoided as a basis for decision-making as measurement errors are simply compounded and the individual components are already available.
PULSE COnTOUR AnALySIS Cardiac output
Pulse contour analysis allows continuous but indirect measurement of cardiac output using a variety of characteristics of the pressure waveform of an arterial line trace to calculate beat-to-beat stroke volume. Estimating cardiac output from the arterial pressure waveform is complex as the waveform is dependent not only on stroke volume but also on aortic impedance that varies both between individuals and within individuals in a nonlinear manner (see Equation 2 ).
Although non-linear, aortic impedance and its relationship to flow can be estimated mathematically using the three-element Windkessel model of the circulation described by Wesseling 85 , comprising of: 1) opposition to pulsatile flow (characteristic impedance); 2) change in aortic volume for a given change in distending pressure (Windkessel compliance); and 3) peripheral arterial resistance.
The Windkessel model is the basis for several commercially available uncalibrated pulse contour analysis devices that derive cardiac output by assuming values for the three model elements based on age, heart rate, mean arterial pressure and the aortic pressure waveform 86, 87 . Although algorithms are becoming more complex 88 , inaccuracy may still be a significant problem. An inability to independently calibrate measured cardiac output prevents change in aortic impedance over time being taken into account when analysing the pressure waveform. The extent of this inaccuracy will depend both on the nature and severity of any haemodynamic derangement. This limits clinical utility, particularly where large variations could be expected 89 .
The PiCCO pulse contour analysis algorithm overcomes some of these limitations by using transcardiopulmonary thermodilution to calibrate cardiac output and measure aortic compliance. Systemic vascular resistance is calculated from the mean arterial pressure and the trans-cardiopulmonary thermodilution-derived cardiac output. The exponential decay time of the arterial pressure curve during the passive diastolic arterial phase is then measured and the aortic compliance (Ca) calculated (Ca=exponential decay time/systemic vascular resistance). Pulse contour analysis for CO=HR.SV where SV=A sys /Z ao stroke volume estimation includes both area under the systolic portion of the arterial waveform and analysis of the shape of the arterial waveform (dP/ dt). Pulse contour analysis-derived cardiac output estimation is then calibrated against a simultaneous trans-cardiopulmonary thermodilution measurement providing a calibration factor (K) for continuous cardiac output by pulse contour analysis (Figure 3) 90 .
Despite the ability to calibrate measurements, the primary limitation of PiCCO pulse contour analysis remains the potential for inaccuracy due to the multitude of input variables required and the assumptions inherent in the derived components of the equation. Pulse contour analysis is also inaccurate in those with arrhythmia, undergoing intra-aortic balloon counterpulsation or other forms of mechanical circulatory assist. Practical limitations include intermittent inaccuracy due to kinking, damping and insufficient zeroing of the arterial line. The site of sampling also has the potential to affect waveform interpretation as acoustic reflections and alterations in vasomotor tone both increase with increasing distance from the aorta although the magnitude of effect may be small enough to still allow reasonable accuracy 91 .
The optimal interval for trans-cardiopulmonary thermodilution recalibration of pulse contour analysis-derived cardiac output is uncertain but is likely to be required more frequently the greater the haemodynamic instability 92, 93 . A novel method for timing recalibration relying on changes in the ratio of stroke volume to pulse pressure as an indicator of alteration in vascular compliance has also recently been proposed 34 .
A number of studies have compared PiCCO pulse contour analysis with pulmonary artery catheter-derived cardiac output and demonstrated variable comparative accuracy 89, [94] [95] [96] [97] [98] . Irrespective of the reference technique chosen, understanding trending reliability and response to sudden changes in haemodynamic conditions in the clinical setting is arguably of greater utility than precision and accuracy of absolute values but to date has not been adequately assessed 10, 99 . Assuming an acceptable level of performance is found to exist, demonstrating efficacy is likely to depend more on the choice of treatment goals and patient population than the specific pulse contour analysis monitor 100 .
Stoke volume variation and pulse pressure variation
Changes in pleural pressure associated with respiration alter the loading conditions of the right and left ventricle and are the major determinant of cyclical variations in stroke volume 101 . During mechanical ventilation, initiation of a positive pressure breath will transiently increase left ventricular stroke volume as the pulmonary veins are compressed increasing blood return to the left side of the heart. Reduced right ventricular stroke volume resulting from a decrease in the pressure gradient for systemic venous return then leads to a reduction in left ventricular stroke volume, albeit with a lag of two to three heartbeats. The extent of the variation over the course of the respiratory cycle is inversely proportional to the mean systemic filling pressure and is exaggerated by absolute or relative hypovolaemia.
Pulse pressure, the difference between the systolic and diastolic blood pressure during a single cardiac cycle, is proportional to the left ventricular stroke volume. Pulse pressure variation, defined as the difference between the maximum and minimum pulse pressure as a proportion of the mean over a defined time period, is therefore also a measure of stroke volume variation. Both pulse pressure variation and stroke volume variation are measured by pulse contour analysis in the PiCCO system. Whether stroke volume variation measured using area under the systolic pressure waveform curve is more accurate in predicting volume responsiveness over the more simple measures of pulse pressure variation and systolic pressure variation is uncertain 81 . Although systolic pressure variation, pulse pressure variation and stroke volume variation of >10 to 13% predict an increase in cardiac output in response to fluid challenge, in clinical practice the generalisability of these finding is limited as they cannot be applied to those with spontaneous ventilatory effort, low airway driving pressures 102 normal physiological conditions the human cardiovascular system is in a volume-responsive state 104, 105 . A measurement that accurately predicts an increase in cardiac output in response to a fluid challenge provides no information on whether additional fluid will be associated with benefit or harm.
Measurement of central venous oxygen saturation
Continuous monitoring of central venous oxygen saturation (S cv O 2 ) monitoring is available with PiCCO 2 through the addition of a CeVOX catheter. The fibreoptic catheter is inserted through the distal lumen of the central venous catheter with the tip placed in the superior vena cava or right atrium. S cv O 2 is a surrogate marker of the overall balance between oxygen delivery and consumption taking into account only the upper body drained by the superior vena cava. The relationship between S cv O 2 and the more established global measure of mixed venous oxygen saturation (S V O 2 ) may be unpredictable during haemodynamic instability, however the two trends appear to move in parallel 106 .
The potential utility of S cv O 2 monitoring arises from the theory that occult tissue hypoxia may persist despite the restoration of arterial pressure and adequate venous filling 107 . As part of an algorithm of early and quantitative resuscitation, S cv O 2 -directed therapy was found to be associated with a significant mortality benefit in a single-centre study of severe sepsis 108 and is a recommendation of the Surviving Sepsis guidelines 71 . The role of S cv O 2 measurement in the critically ill is still uncertain. Localised imbalance in oxygen utilisation may still exist without an apparent global abnormality and monitoring lactate clearance may provide a viable systemic alternative without the need for more invasive monitoring 109 . Furthermore, both high and low S cv O 2 may be associated with worse outcome, complicating interpretation 110.
COnCLUSIOn
There is considerable variation in the utilisation of advanced haemodynamic monitoring devices resulting from the lack of definitive efficacy data to support their use. The choice of monitor requires an understanding of its underlying physiological basis, risks associated with insertion and ongoing use, and the range and validity of the data provided. These factors must be considered within the clinical circumstances of proposed use and should take into account the extent to which the data will be directly relied upon to guide therapeutic decision-making as well as the potential implications of those decisions.
The requirement for intra-arterial and central venous catheterisation limits the use of PiCCO to those with evolving critical illness or at high risk of complex and severe haemodynamic derangement, however these are also the patients most likely to benefit from advanced haemodynamic monitoring. Although the PiCCO monitor has been available for over 10 years and numerous comparative studies have been published, the validity and utility of some of its parameters remains to be established in the settings of its intended use.
The greatest potential advantage of PiCCO in comparison to many other cardiac output monitors is in its ability to measure and integrate a wide array of haemodynamic data. given the potential for harm from many of the interventions initiated on the basis of the results of advanced haemodynamic measurements, conclusive studies designed to demonstrate efficacy are required. In the case of PiCCO, benefit is most likely to results when definitive studies provide validated parameters in the population of interest that can then be integrated into clinical decision-making. Continued technological advances and increased understanding of the appropriate methods with which to compare monitors coupled with evaluation of clinically important endpoints will lead to a greater strength in the evidence base for device selection in the coming years.
